StreetInsider.com News Articles

Decoy Therapeutics nominates Patricia Gauthier for board election

Wed, 03 Jun 2026 08:01:12 -0400

Decoy Therapeutics Inc. (NASDAQ: DCOY) announced the nomination of Patricia Gauthier as a Class II director for election at the company's annual stockholders meeting on July 14, 2026.

Gauthier currently serves as Senior Vice President and Regional Head for Australia, Canada and the United Kingdom at Moderna, a position she has held since 2025. In this role, she leads strategy and operations across biomanufacturing, national health security partnerships and commercialization for approximately 500 employees.

Prior to her current position, Gauthier served as General Manager of Moderna Canada, where she built the affiliate from inception and supported delivery of more than 50 million

Decoy Therapeutics nominates Patricia Gauthier for board election

Wed, 03 Jun 2026 08:01:12 -0400

Decoy Therapeutics Inc. (NASDAQ: DCOY) announced the nomination of Patricia Gauthier as a Class II director for election at the company's annual stockholders meeting on July 14, 2026.

Prior to her current position, Gauthier served as General Manager of Moderna Canada, where she built the affiliate from inception and supported delivery of more than 50 million

Decoy Therapeutics nominates Patricia Gauthier for board election

Wed, 03 Jun 2026 08:01:12 -0400

Decoy Therapeutics Inc. (NASDAQ: DCOY) announced the nomination of Patricia Gauthier as a Class II director for election at the company's annual stockholders meeting on July 14, 2026.

Prior to her current position, Gauthier served as General Manager of Moderna Canada, where she built the affiliate from inception and supported delivery of more than 50 million

Decoy Therapeutics nominates Patricia Gauthier for board election

Wed, 03 Jun 2026 08:01:12 -0400

Decoy Therapeutics Inc. (NASDAQ: DCOY) announced the nomination of Patricia Gauthier as a Class II director for election at the company's annual stockholders meeting on July 14, 2026.

Prior to her current position, Gauthier served as General Manager of Moderna Canada, where she built the affiliate from inception and supported delivery of more than 50 million

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

Wed, 03 Jun 2026 08:00:00 -0400

CAMBRIDGE, Mass., June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced the nomination of Patricia Gauthier, MBA, LL.B., as a Class II director. Ms. Gauthier's nomination will be voted on at the Company's 2026 Annual Meeting of Stockholders on July 14, 2026.

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

Wed, 03 Jun 2026 08:00:00 -0400

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

Wed, 03 Jun 2026 08:00:00 -0400

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

Wed, 03 Jun 2026 08:00:00 -0400

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

Wed, 03 Jun 2026 08:00:00 -0400

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

Wed, 03 Jun 2026 08:00:00 -0400

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

Wed, 03 Jun 2026 08:00:00 -0400

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

Wed, 03 Jun 2026 08:00:00 -0400

Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

Mon, 01 Jun 2026 07:00:00 -0400